-

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient

Recognition Based on Commitment to Collaboration, Quality and Service

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was celebrated September 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

#FreseniusKabi has been named the 2023 Supplier Partner of the Year by @VizientInc, the nation’s largest provider-driven #healthcare performance improvement company.

Share

According to Vizient, the Supplier Partner of the Year demonstrates an unmatched willingness to improve performance and deliver on Vizient’s mission to strengthen Vizient provider customers’ delivery of high-value care. With actively engaged senior executives, the Supplier Partner of the Year provides comprehensive contract access across product/service lines and participates widely in performance improvement solutions and programs, proactively engaging the broader Vizient enterprise and bringing high-value solutions to unmet market needs.

“This recognition as Vizient’s Supplier Partner of the Year reflects our team’s commitment to collaboration and innovation to enhance quality of care and patient safety while controlling costs,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA. “At every level of our organization, we are focused on helping customers find new solutions for meeting the challenges of today’s health care environment.”

The award marks the second time Fresenius Kabi has been named Supplier Partner of the Year since 2016. In addition, Fresenius Kabi has been named Vizient’s Pharmaceutical Partner of the Year three times, and twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year in this time period.

“We are excited to recognize Fresenius Kabi as this year’s winner of the prestigious Supplier Partner of the Year Award. Fresenius Kabi has demonstrated how suppliers can work differently with Vizient to ensure that together we are delivering on our provider customer’s holistic needs relative to cost, quality, and market performance. They have also shown exemplary commitment to quality and service, putting providers and the patients they care for at the center of all they do,” said Simrit Sandhu, executive vice president, clinical supply solutions, Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® (ustekinumab-aauz) in a 45 mg/0.5 mL single-dose vial for subcutaneous injection. Otulfi® is a prescription medicine and the brand name for Fresenius Kabi’s FDA-approved biosimilar of the reference product, Stelara® (ustekinumab). With this addition, Fresenius Kabi now offers...

Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has launched Rocuronium Bromide Injection Room Temperature Stable (RTS), the first formulation of Rocuronium Bromide Injection that does not require refrigeration. Rocuronium Bromide Injection RTS was formulated to be stored at room temperature, eliminating the need for refrigeration, which is expected to streamline log...

Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced two new products in its Simplist® portfolio of ready-to-administer prefilled syringes: Simplist® Ephedrine Sulfate Injection, USP and Simplist® Succinylcholine Chloride Injection, USP. Both medications are used in anesthesia and critical care, and their introduction extends the Simplist line...
Back to Newsroom